《转化医学学会关于EGFR突变型肺癌术后管理的共识（2019年版）》勘误
Erratum to Society for Translational Medicine consensus on postoperative management of EGFR-mutant lung cancer (2019 edition).
出版信息
Transl Lung Cancer Res. 2020 Jun;9(3):944. doi: 10.21037/tlcr.2020.03.39.
Abstract
[This corrects the article DOI: 10.21037/tlcr.2019.12.14.].
摘要
[本文更正了文章的数字对象标识符：10.21037/tlcr.2019.12.14。]
相似文献
1
Erratum to Society for Translational Medicine consensus on postoperative management of EGFR-mutant lung cancer (2019 edition).《转化医学学会关于EGFR突变型肺癌术后管理的共识（2019年版）》勘误
Transl Lung Cancer Res. 2020 Jun;9(3):944. doi: 10.21037/tlcr.2020.03.39.
2
Society for Translational Medicine consensus (2019 edition) shows an option for postoperative management of EGFR-mutant lung cancer.转化医学学会共识（2019年版）展示了表皮生长因子受体（EGFR）突变型肺癌术后管理的一种选择。
J Thorac Dis. 2020 Aug;12(8):4561-4563. doi: 10.21037/jtd.2020.04.34.
3
Society for Translational Medicine consensus on postoperative management of EGFR-mutant lung cancer (2019 edition).转化医学学会关于表皮生长因子受体（EGFR）突变型肺癌术后管理的共识（2019年版）
Transl Lung Cancer Res. 2019 Dec;8(6):1163-1173. doi: 10.21037/tlcr.2019.12.14.
4
Erratum to alteration in -mutated lung adenocarcinoma leads to histological small-cell carcinoma transformation under EGFR-TKI treatment.《-突变型肺腺癌的改变在EGFR-TKI治疗下导致组织学小细胞癌转化》勘误
Transl Lung Cancer Res. 2022 Nov;11(11):2358-2359. doi: 10.21037/tlcr-2022-8.
5
Erratum to combination MET- and EGFR-directed therapy in MET-overexpressing non-small cell lung cancers: time to move on to better biomarkers?《MET过表达的非小细胞肺癌中MET和EGFR联合靶向治疗的勘误：是时候转向更好的生物标志物了吗？》
Transl Lung Cancer Res. 2017 Oct;6(5):611. doi: 10.21037/tlcr.2017.08.07.
6
Erratum to identification of GPX4 as a therapeutic target for lung adenocarcinoma after EGFR-TKI resistance.《EGFR-TKI耐药后GPX4作为肺腺癌治疗靶点的鉴定》勘误
Transl Lung Cancer Res. 2022 Aug;11(8):1731-1733. doi: 10.21037/tlcr-2022-4.
7
Erratum: Precision radiotherapy for patients with locally advanced non-small cell lung cancer in the era of immunotherapy and precision medicine.勘误：免疫治疗与精准医学时代局部晚期非小细胞肺癌患者的精准放疗。
Transl Lung Cancer Res. 2019 Aug;8(4):558. doi: 10.21037/tlcr.2019.04.11.
8
Erratum to the importance of incorporating smoking cessation into lung cancer screening.《将戒烟纳入肺癌筛查的重要性》勘误
Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S303. doi: 10.21037/tlcr.2018.09.02.
9
[Erratum: Chinese expert consensus on day surgery management of lung cancer (2024 edition).].[勘误：《中国肺癌日间手术管理专家共识（2024年版）》。]
Zhongguo Fei Ai Za Zhi. 2024 Jul 20;27(7):564. doi: 10.3779/j.issn.1009-3419.2024.103.01.
10
Erratum to latest CT technologies in lung cancer screening: protocols and radiation dose reduction.《肺癌筛查中的最新CT技术：方案与辐射剂量降低》勘误
Transl Lung Cancer Res. 2021 Apr;10(4):2101-2102. doi: 10.21037/tlcr-2021-2.
本文引用的文献
1
Society for Translational Medicine consensus on postoperative management of EGFR-mutant lung cancer (2019 edition).转化医学学会关于表皮生长因子受体（EGFR）突变型肺癌术后管理的共识（2019年版）
Transl Lung Cancer Res. 2019 Dec;8(6):1163-1173. doi: 10.21037/tlcr.2019.12.14.
Zotero 插件